Sichuan Hebang Biotechnology Co Ltd
Sichuan Hebang Biotechnology Corporation Limited provides agricultural, chemical, and new material products. It offers biological pesticides, biological veterinary drugs, and methionine products; and sodium carbonate, ammonium chloride, soda ash, diglyphosate, glyphosate, and brine. The company provides original glass and smart glass, special glass, low-e coated glass, and photovoltaic packaging … Read more
Sichuan Hebang Biotechnology Co Ltd (603077) - Total Liabilities
Latest total liabilities as of September 2025: CN¥10.53 Billion CNY
Based on the latest financial reports, Sichuan Hebang Biotechnology Co Ltd (603077) has total liabilities worth CN¥10.53 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sichuan Hebang Biotechnology Co Ltd - Total Liabilities Trend (2009–2024)
This chart illustrates how Sichuan Hebang Biotechnology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sichuan Hebang Biotechnology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Sichuan Hebang Biotechnology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Peyto Exploration&Development Corp
PINK:PEYUF
|
USA | $2.66 Billion |
|
Prestige Estates Projects Limited
NSE:PRESTIGE
|
India | ₹503.31 Billion |
|
Nexi S.p.A
PINK:NEXPF
|
USA | $14.16 Billion |
|
Outfront Media Inc. (REIT)
F:76C
|
Germany | €4.43 Billion |
|
ABM Industries Incorporated
NYSE:ABM
|
USA | $3.67 Billion |
|
SICC Co. Ltd.
SHG:688234
|
China | CN¥2.32 Billion |
|
TOMY Company, Ltd.
OTCGREY:TOMYF
|
USA | $58.40 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down Sichuan Hebang Biotechnology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sichuan Hebang Biotechnology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sichuan Hebang Biotechnology Co Ltd (2009–2024)
The table below shows the annual total liabilities of Sichuan Hebang Biotechnology Co Ltd from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥10.64 Billion | +146.14% |
| 2023-12-31 | CN¥4.32 Billion | -0.35% |
| 2022-12-31 | CN¥4.34 Billion | +32.09% |
| 2021-12-31 | CN¥3.29 Billion | -4.30% |
| 2020-12-31 | CN¥3.43 Billion | +13.25% |
| 2019-12-31 | CN¥3.03 Billion | +45.14% |
| 2018-12-31 | CN¥2.09 Billion | +13.88% |
| 2017-12-31 | CN¥1.83 Billion | -14.78% |
| 2016-12-31 | CN¥2.15 Billion | -53.37% |
| 2015-12-31 | CN¥4.62 Billion | +5.36% |
| 2014-12-31 | CN¥4.38 Billion | +91.08% |
| 2013-12-31 | CN¥2.29 Billion | +39.63% |
| 2012-12-31 | CN¥1.64 Billion | -29.88% |
| 2011-12-31 | CN¥2.34 Billion | +9.19% |
| 2010-12-31 | CN¥2.14 Billion | -11.74% |
| 2009-12-31 | CN¥2.43 Billion | -- |